{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:48:17Z","timestamp":1760057297886,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jem-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Emergency Medicine"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.jemermed.2007.08.058","type":"journal-article","created":{"date-parts":[[2008,1,30]],"date-time":"2008-01-30T10:06:31Z","timestamp":1201687591000},"page":"417-428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Medical Management of Acute Coronary Syndromes and Potential Roles for New Antithrombotic Agents"],"prefix":"10.1016","volume":"34","author":[{"suffix":"Jr.","given":"Charles V.","family":"Pollack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. David","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"unstructured":"Braunwald E, Antman EM, Beasley JW, et al. ACC\/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina); 2002. Available at: http:\/\/www.acc.org\/clinical\/guidelines\/unstable\/unstable.pdf. Accessed June 23, 2006.","key":"10.1016\/j.jemermed.2007.08.058_bib1"},{"author":"Antman","key":"10.1016\/j.jemermed.2007.08.058_bib2"},{"key":"10.1016\/j.jemermed.2007.08.058_bib3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.amjcard.2005.06.056","article-title":"Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes","volume":"96","author":"Rao","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jemermed.2007.08.058_bib4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJM199703203361207","article-title":"Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction","volume":"336","author":"Collins","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2007.08.058_bib5","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis","volume":"355","author":"Eikelboom","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2007.08.058_bib6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(01)05775-0","article-title":"Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction","volume":"358","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2007.08.058_bib7","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(02)07495-0","article-title":"Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data","volume":"359","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2007.08.058_bib8","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jemermed.2007.08.058_bib9","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1378\/chest.125.5.1616","article-title":"Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome","volume":"125","author":"Macie","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jemermed.2007.08.058_bib10","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1001\/jama.292.17.2096","article-title":"Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative","volume":"292","author":"Bhatt","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jemermed.2007.08.058_bib11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1055\/s-2004-817692","article-title":"Treatment algorithms and critical pathways for acute coronary syndromes","volume":"3","author":"Cannon","year":"2003","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.jemermed.2007.08.058_bib12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1161\/01.CIR.0000155258.44268.F8","article-title":"Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3\/4 analysis","volume":"111","author":"Nallamothu","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jemermed.2007.08.058_bib13","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0002-8703(03)00439-3","article-title":"Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies","volume":"146","author":"Waters","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.jemermed.2007.08.058_bib14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1053\/euhj.2001.3081","article-title":"Management of acute coronary syndromes","volume":"23","author":"Fox","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jemermed.2007.08.058_bib15","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1161\/CIRCULATIONAHA.105.586198","article-title":"Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry)","volume":"113","author":"Kalla","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jemermed.2007.08.058_bib16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/hrt.2003.031237","article-title":"Contemporary management of acute coronary syndromes: does the practice match the evidence?","volume":"91","author":"Carruthers","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.jemermed.2007.08.058_bib17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial","volume":"295","author":"Kastrati","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jemermed.2007.08.058_bib18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"unstructured":"Montalescot G. STEEPLE: safety and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation. Clinical trial update session: annual meeting of the European Society of Cardiology Congress; September 3\u20137, 2005; Stockholm, Sweden.","key":"10.1016\/j.jemermed.2007.08.058_bib19"},{"key":"10.1016\/j.jemermed.2007.08.058_bib20","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2007.08.058_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jama.293.3.349","article-title":"A simplified approach to the management of non-ST-segment elevation acute coronary syndromes","volume":"293","author":"Gluckman","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jemermed.2007.08.058_bib22","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1161\/01.CIR.0000165556.44271.BE","volume":"111","author":"Gibler","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jemermed.2007.08.058_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(94)91161-4","article-title":"Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2007.08.058_bib24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(96)02514-7","article-title":"Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour","volume":"348","author":"Boersma","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2007.08.058_bib25","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2007.08.058_bib26","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJM199710163371603","article-title":"A comparison of reteplase with alteplase for acute myocardial infarction","volume":"337","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2007.08.058_bib27","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(00)05059-5","article-title":"Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb\/IIIa inhibition: the GUSTO V randomised trial","volume":"357","author":"Topol","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2007.08.058_bib28","doi-asserted-by":"crossref","first-page":"90S","DOI":"10.1592\/phco.22.10.90S.33617","article-title":"The biology of thrombin in acute coronary syndromes","volume":"22","author":"Nappi","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jemermed.2007.08.058_bib29","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.1592\/phco.22.10.97S.33614","article-title":"The role of thrombin inhibition during percutaneous coronary intervention","volume":"22","author":"Wittkowsky","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jemermed.2007.08.058_bib30","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0755-4982(05)84181-8","article-title":"New anticoagulants in ischemic heart disease","volume":"34","author":"Verheugt","year":"2005","journal-title":"Presse Med"},{"key":"10.1016\/j.jemermed.2007.08.058_bib31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-2003-40667","article-title":"Antithrombotic drugs in vascular medicine: a historical perspective","volume":"3","author":"Schror","year":"2003","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.jemermed.2007.08.058_bib32","first-page":"65","article-title":"GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction","volume":"336","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2007.08.058_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0140-6736(90)91590-7","article-title":"In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin","volume":"336","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2007.08.058_bib34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0140-6736(92)91893-D","article-title":"ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction","volume":"339","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2007.08.058_bib35","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/0735-1097(88)92635-6","article-title":"Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2","volume":"12","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jemermed.2007.08.058_bib36","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"unstructured":"Chen Z. COMMIT\/CCS-2: Randomized, placebo-controlled trial of adding clopidogrel to aspirin in 46,000 acute myocardial infarction patients. Scientific session: Annual Meeting of the American College of Cardiology; March 3, 2006; Orlando, FL.","key":"10.1016\/j.jemermed.2007.08.058_bib37"},{"key":"10.1016\/j.jemermed.2007.08.058_bib38","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","article-title":"Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction","volume":"354","author":"Antman","year":"2006","journal-title":"N Engl J Med"},{"doi-asserted-by":"crossref","unstructured":"Gibson M. PCI-ExTRACT-TIMI 25: Percutaneous coronary intervention outcomes among patients treated with enoxaparin versus unfractionated heparin following fibrinolytic administration for ST-elevation myocardial infarction. Clinical trial update: World Congress of Cardiology meeting; September 4, 2006; Barcelona, Spain.","key":"10.1016\/j.jemermed.2007.08.058_bib39","DOI":"10.1016\/j.jacc.2007.01.093"},{"issue":"Suppl 1","key":"10.1016\/j.jemermed.2007.08.058_bib40","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.3949\/ccjm.72.Suppl_1.S2","article-title":"A pharmacologic overview of current and emerging anticoagulants","volume":"72","author":"Nutescu","year":"2005","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jemermed.2007.08.058_bib41","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jemermed.2007.08.058_bib42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jama.293.4.427","article-title":"Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation","volume":"293","author":"Yusuf","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jemermed.2007.08.058_bib43","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina","volume":"276","author":"Oler","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.jemermed.2007.08.058_bib44","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(05)67222-4","article-title":"5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2007.08.058_bib45","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/01.CIR.0000050144.67910.13","article-title":"Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb\/IIIa inhibitor eptifibatide","volume":"107","author":"Goodman","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jemermed.2007.08.058_bib46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.292.1.55","article-title":"Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial","volume":"292","author":"Blazing","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jemermed.2007.08.058_bib47","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jemermed.2007.08.058_bib48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jama.292.1.89","article-title":"Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview","volume":"292","author":"Petersen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jemermed.2007.08.058_bib49","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2007.08.058_bib50","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1001\/jama.1988.03410150107041","article-title":"Overview of results of randomized clinical trials in heart disease. II","volume":"260","author":"Yusuf","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.jemermed.2007.08.058_bib51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy\u2014I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.jemermed.2007.08.058_bib52","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/sj.bjp.0702276","article-title":"Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro","volume":"126","author":"Weber","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jemermed.2007.08.058_bib53","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2007.08.058_bib54","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJM199506083322306","article-title":"Platelet glycoprotein IIb\/IIIa receptors in cardiovascular medicine","volume":"332","author":"Lefkovits","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2007.08.058_bib55","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.semvascsurg.2005.05.002","article-title":"Heparin and other rapidly acting anticoagulants","volume":"18","author":"Hyers","year":"2005","journal-title":"Semin Vasc Surg"},{"unstructured":"Angiomax\u00ae [package insert]. Bedford, OH: BenVenue Laboratories; 2005.","key":"10.1016\/j.jemermed.2007.08.058_bib56"},{"unstructured":"ARGATROBAN [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005.","key":"10.1016\/j.jemermed.2007.08.058_bib57"}],"container-title":["The Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467907007263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467907007263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:17:56Z","timestamp":1760026676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0736467907007263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0736467907007263"],"URL":"https:\/\/doi.org\/10.1016\/j.jemermed.2007.08.058","relation":{},"ISSN":["0736-4679"],"issn-type":[{"type":"print","value":"0736-4679"}],"subject":[],"published":{"date-parts":[[2008,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Medical Management of Acute Coronary Syndromes and Potential Roles for New Antithrombotic Agents","name":"articletitle","label":"Article Title"},{"value":"The Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jemermed.2007.08.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}